Adaptive Biotechnologies Corporation (ADPT) vs Doximity, Inc. (DOCS)
A side-by-side comparison of Adaptive Biotechnologies Corporation and Doximity, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ADPT
Adaptive Biotechnologies Corporation
$28.20HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
DOCS
Doximity, Inc.
$28.65HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
Total return — ADPT vs DOCS
growth of $100 · dividends reinvested · last 5yADPT -25.9% (-5.8%/yr)DOCS -46.1% (-11.6%/yr)ADPT compounded faster over this window
ADPT DOCS
ADPT vs DOCS: by the numbers
- •DOCS is the larger company ($5.36B vs $4.51B market cap).
- •DOCS is profitable (25.48% net margin) while ADPT runs a net loss (-20.73%).
- •DOCS grew revenue faster over the past five years (21.94% vs 18.22% CAGR).
Metrics side by side
Valuation
| Metric | ADPT | DOCS |
|---|---|---|
| P/E ratio | N/A | 33.71 |
| Forward P/E | N/A | 21.26 |
| PEG ratio | N/A | 0.65 |
| P/S ratio | 14.65 | 8.17 |
| P/B ratio | 31.58 | 5.85 |
| EV / EBITDA | N/A | 24.07 |
| FCF yield | N/A | 5.59% |
Profitability
| Metric | ADPT | DOCS |
|---|---|---|
| Gross margin | 75.44% | 88.07% |
| Operating margin | -20.62% | 29.60% |
| Net margin | -20.73% | 25.48% |
| ROE | -44.68% | 18.24% |
| ROIC | -6.67% | 15.35% |
Growth (annualized)
| Metric | ADPT | DOCS |
|---|---|---|
| Revenue CAGR (5Y) | 18.22% | 21.94% |
| EPS CAGR (5Y) | N/A | 54.32% |
| FCF CAGR (5Y) | N/A | 23.75% |
| Total return CAGR (5Y) | -1.77% | -18.23% |
Frequently asked
- Which has grown faster, ADPT or DOCS?
- Over the past five years, DOCS grew revenue faster — ADPT at a 18.22% CAGR versus DOCS at 21.94%.
- Is ADPT or DOCS more profitable?
- DOCS runs the higher net margin — ADPT at -20.73% versus DOCS at 25.48%.
- How have ADPT and DOCS total returns compared?
- Over the past 5 years, ADPT delivered -1.77% and DOCS delivered -18.23% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Doximity P/E ratioAdaptive Biotechnologies ROEDoximity ROEAdaptive Biotechnologies operating marginDoximity operating marginAdaptive Biotechnologies revenue growthDoximity revenue growthAdaptive Biotechnologies free cash flowDoximity free cash flow
Adaptive Biotechnologies & Doximity appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.